ReviewPeptides2007
Stress, NPY and vascular remodeling: Implications for stress-related diseases.
Review in Peptides, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 99 citations in OpenAlex.
- Neuropeptide Y and peptide YY differentially modulate bitter- and fatty acid-evoked responses in human fungiform taste bud cells.American journal of physiology. Cell physiology · 2026Article
- The therapeutic effects of labetalol in chronic stress- and immuno-agonist-induced cough hypersensitivity and lung inflammation involve reducing interferon-γ-producing T lymphocytes.ERJ open research · 2026Article
- Neuropeptide Y in cancer-biological functions and potential clinical implications.Cancer metastasis reviews · 2025Review
- Enrichment and fragmentation approaches for enhanced detection and characterization of endogenous glycosylated neuropeptides.Proteomics · 2023Article
- Neuropeptide Y Promotes Human M2 Macrophage Polarization and Enhances p62/SQSTM1-Dependent Autophagy and NRF2 Activation.International journal of molecular sciences · 2022Article
- Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?Cancers · 2022Review
- Regulation of neuropeptide Y in body microenvironments and its potential application in therapies: a review.Cell & bioscience · 2021Review
- Updated Role of Neuropeptide Y in Nicotine-Induced Endothelial Dysfunction and Atherosclerosis.Frontiers in cardiovascular medicine · 2021Review
- Anxiety Is Associated With DPPIV Alterations in Children With Selective Mutism and Social Anxiety Disorder: A Pilot Study.Frontiers in psychiatry · 2021Article
- Quantification of Neuropeptide Y with Picomolar Sensitivity Enabled by Guided-Mode Resonance Biosensors.Sensors (Basel, Switzerland) · 2019Article
- Minimally invasive laser Doppler flowmetry is suitable for serial bone perfusion measurements in mice.Bone reports · 2019Article
- Placental Neuropeptide Y ( NPY) and NPY receptors expressions and serum NPY levels in preeclampsia.Experimental biology and medicine (Maywood, N.J.) · 2019Article
- Substance P Receptor in the Rat Heart and Regulation of Its Expression in Long-Term Diabetes.Frontiers in physiology · 2018Article
- High-Throughput Screening Assay Datasets from the PubChem Database.Chemical informatics (Wilmington, Del.) · 2017Article
- The stress of maternal separation causes misprogramming in the postnatal maturation of rat resistance arteries.American journal of physiology. Heart and circulatory physiology · 2015Article
- Neuropeptide Y regulates the hematopoietic stem cell microenvironment and prevents nerve injury in the bone marrow.The EMBO journal · 2015Article
- Article
- Article
- Article
- Emerging drugs for the treatment of diabetic ulcers.Expert opinion on emerging drugs · 2013Review
Corrections and comments
- Erratum issuedAbe, Ken [added]
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Neuropeptide Y (NPY) has long been known to be involved in stress, centrally as an anxiolytic neuromodulator, and peripherally as a sympathetic nerve- and in some species, platelet-derived vasoconstrictor. The peptide is also a vascular mitogen, via Y1/Y5, and is angiogenic via Y2/Y5 receptors. Arterial injury activates platelet NPY and vascular Y1 receptors, inducing medial hypertrophy and neointima formation. Exogenous NPY, dipeptidyl peptidase IV (DPPIV, forming an Y2/Y5-selective agonist) and chronic stress augment these effects and occlude vessels with atherosclerotic-like lesions, containing thrombus and lipid-laden macrophages. Y1 antagonist blocks stress-induced vasoconstriction and post-angioplasty occlusions, and hence may be therapeutic in angina and atherosclerosis/restenosis. Conversely, tissue ischemia activates neuronal and platelet-derived NPY, Y2/Y5 and DPPIV, which stimulate angiogenesis/arteriogenesis. NPY-Y2-DPPIV agonists may be beneficial for ischemic revascularization and wound healing, whereas antagonists may be therapeutic in retinopathy, tumors, and obesity. Since stress is an underestimated risk factor in many of these conditions, NPY-based drugs may offer new treatment possibilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.